New Results
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
Jeffrey F. Hiken, James I. McDonald, Keith F. Decker, Cesar Sanchez, Jeremy Hoog, Nathan D. VanderKraats, Kyle L. Jung, Margaret Akinhanmi, Matthew J. Ellis, John R. Edwards
doi: https://doi.org/10.1101/056770
Jeffrey F. Hiken
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
James I. McDonald
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Keith F. Decker
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Cesar Sanchez
2Pontificia Universidad Catolica de Chile, Santiago, Chile
Jeremy Hoog
3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
Nathan D. VanderKraats
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Kyle L. Jung
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Margaret Akinhanmi
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Matthew J. Ellis
4Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA
John R. Edwards
1Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, Missouri, USA
Article usage
Posted June 02, 2016.
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
Jeffrey F. Hiken, James I. McDonald, Keith F. Decker, Cesar Sanchez, Jeremy Hoog, Nathan D. VanderKraats, Kyle L. Jung, Margaret Akinhanmi, Matthew J. Ellis, John R. Edwards
bioRxiv 056770; doi: https://doi.org/10.1101/056770
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
Jeffrey F. Hiken, James I. McDonald, Keith F. Decker, Cesar Sanchez, Jeremy Hoog, Nathan D. VanderKraats, Kyle L. Jung, Margaret Akinhanmi, Matthew J. Ellis, John R. Edwards
bioRxiv 056770; doi: https://doi.org/10.1101/056770
Subject Area
Subject Areas
- Biochemistry (11744)
- Bioengineering (8751)
- Bioinformatics (29193)
- Biophysics (14968)
- Cancer Biology (12094)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18303)
- Genetics (12244)
- Genomics (16801)
- Immunology (11866)
- Microbiology (28082)
- Molecular Biology (11592)
- Neuroscience (60959)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)